The Maryland biotech also received $30 million in milestone payments after licensing retifanlimab to Incyte Corp., and could receive more if the drug, now in clinical trials, is later approved. MacroGenics separately expects to start a phase 2/3 study by year’s end of a candidate in patients with a form of advanced prostate cancer, and has another candidate in early-stage studies for colorectal cancer, nonsmall cell lung cancer, metastatic prostate cancer and melanoma.
Md. biotech strikes deal with Gilead potentially worth more than $1.7B
October 18, 2022
